SurModics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, SurModics sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).

4 total trials 1 currently recruiting 3 completed early-phase tilt upper quartile by trial count

SurModics: 4 sponsored US clinical trials, 1 recruiting.

SurModics sponsors 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Limb Ischemia, with 1 trials.

Upper-quartile sponsor footprint

SurModics sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

What is open in the SurModics pipeline

1 recruiting of 4 indexed (25% open); 3 completed (75%).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: Acute Limb Ischemia (1 trial), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

SurModics: open-pipeline peers nationwide

Peers matched on 4 registered trials and 25% open enrollment, not the therapeutic-area sidebar.

SurModics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 3456789 0%20%40%60%80% Total trials Recruiting share SurModics4D pharma60 Degrees PharmaceuticalsA2 BiotherapeuticsAbdul Latif Jameel Poverty Action LabAB ScienceAbbott Point of CareAccutar BiotechnologyAdrienne G. Waks
SurModics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

SurModics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 4 trials (± recruiting share)

Sponsors near 25% open enrollment (± trial volume)

What to do with this SurModics page

4 registered trials is a research-attention snapshot, not an endorsement of SurModics or any single study.

  • 1 of SurModics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Acute Limb Ischemia is the condition SurModics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Limb Ischemia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

SurModics pipeline card: 4 registered trials from official public datasets.Report a data error.